immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide(PresseBox) ( Tübingen and Martinsried/Munich, )
Patent EP1794190 will cover an additional MHC-Class II peptide. Both patents add to the broad IP portfolio of immatics.
Further expanding its patent portfolio covering other products, immatics has been granted US patent 7,528,224 covering a peptide encoded by the MUC-1 gene; this peptide is able to elicit an immune response against tumors overexpressing MUC-1. immatics has already obtained patent protection for this peptide in Europe.
"The first TUMAP patent owned by immatics was granted in 2004 and patent protection for peptide sequences has remained unchallenged in all major pharma markets including North America, EU, and Japan. Our IP position is therefore very strong," said Niels Emmerich, Managing Director and COO of immatics. "We will continue to expand our patent portfolio by filing patents for individual TUMAPs, our peptide-based products and our technologies in all major countries and pharma markets."
IMA901 is an off-the-shelf cancer vaccines consisting of multiple fully synthetic tumorassociated peptides (TUMAPs), representing tumor antigens relevant for renal cell carcinoma. IMA901 is currently in a European multi-center Phase II clinical trial. The TUMAPs contained in IMA901, were identified by analyzing the HLA peptide repertoire of a large number of primary tumor tissues and were selected based on their ability to activate TUMAP-specific cytotoxic T cells and T helper cells.